240 related articles for article (PubMed ID: 23026278)
21. A Case of Alpha-Fetoprotein-Producing Adenocarcinoma of the Esophagogastric Junction in which Long-Term Survival Was Achieved by Means of Individualized Multidisciplinary Therapy.
Tanaka K; Fujiya M; Ijiri M; Takahashi K; Ando K; Nomura Y; Ueno N; Kashima S; Goto T; Sasajima J; Ito T; Moriichi K; Mizukami Y; Tanabe H; Okumura T
J Gastrointest Cancer; 2019 Sep; 50(3):617-620. PubMed ID: 29457212
[No Abstract] [Full Text] [Related]
22. Concise Commentary: It's All Downhill from Here-How Diagnostic and Therapeutic Advances May Decrease the Incidence Rates of Gastroesophageal Junction and Esophageal Adenocarcinoma.
Gamboa A; Naik R
Dig Dis Sci; 2024 Jan; 69(1):254-255. PubMed ID: 37914891
[No Abstract] [Full Text] [Related]
23. Management of Barrett's esophageal carcinoma.
Miyazaki T; Inose T; Tanaka N; Yokobori T; Suzuki S; Ozawa D; Sohda M; Nakajima M; Fukuchi M; Kato H; Kuwano H
Surg Today; 2013 Apr; 43(4):353-60. PubMed ID: 23283352
[TBL] [Abstract][Full Text] [Related]
24. Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation.
Taketa T; Correa AM; Suzuki A; Blum MA; Chien P; Lee JH; Welsh J; Lin SH; Maru DM; Erasmus JJ; Bhutani MS; Weston B; Rice DC; Vaporciyan AA; Hofstetter WL; Swisher SG; Ajani JA
Oncology; 2012; 83(5):300-4. PubMed ID: 22964903
[TBL] [Abstract][Full Text] [Related]
25. Adenocarcinoma at the gastroesophageal junction.
Al-Haddad S; Chang AC; De Hertogh G; Grin A; Langer R; Sagaert X; Salemme M; Streutker CJ; Soucy G; Tripathi M; Upton MP; Vieth M; Villanacci V
Ann N Y Acad Sci; 2014 Sep; 1325():211-25. PubMed ID: 25266027
[TBL] [Abstract][Full Text] [Related]
26. Western strategy for EGJ carcinoma.
Giacopuzzi S; Bencivenga M; Weindelmayer J; Verlato G; de Manzoni G
Gastric Cancer; 2017 Mar; 20(Suppl 1):60-68. PubMed ID: 28039533
[TBL] [Abstract][Full Text] [Related]
27. (Neo)-adjuvant chemo(-radio) therapy for adenocarcinomas of the gastroesophageal junction and the stomach in the West.
Wilke H; Lordick F; Meyer HJ; Stahl M
Dig Surg; 2013; 30(2):112-8. PubMed ID: 23867587
[TBL] [Abstract][Full Text] [Related]
28. Optimal management of esophageal adenocarcinoma: should we be CROSS?
Smyth EC; Waddell TS; Cunningham D
J Clin Oncol; 2014 Sep; 32(27):3080-1. PubMed ID: 25071100
[No Abstract] [Full Text] [Related]
29. Are cancers of the esophagus, gastroesophageal junction, and cardia one disease, two, or several?
Rusch VW
Semin Oncol; 2004 Aug; 31(4):444-9. PubMed ID: 15297937
[TBL] [Abstract][Full Text] [Related]
30. Individualized surgical strategies for cancer of the esophagogastric junction.
Stein HJ; Feith M; Siewert JR
Ann Chir Gynaecol; 2000; 89(3):191-8. PubMed ID: 11079787
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant or neoadjuvant therapy for operable esophagogastric cancer?
Moorcraft SY; Smyth EC; Cunningham D
Gastric Cancer; 2015 Jan; 18(1):1-10. PubMed ID: 24638977
[TBL] [Abstract][Full Text] [Related]
32. [Comparison of recurrence patterns in esophageal carcinoma after surgery alone and surgery after neoadjuvant chemoradiotherapy: a secondary analysis of the CROSS study].
Hautmann MG; Kölbl O
Strahlenther Onkol; 2014 Jul; 190(7):696-8. PubMed ID: 25061651
[No Abstract] [Full Text] [Related]
33. Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran.
Farhan F; Ghalehtaki R; Mahdavi-Seresht S; Meysamie A; Yamrali M; Farazmand B; Mohammadi N; Saraee E; Mir MR; Mir A; Lashkari M; Salarvand S; Esmati E; Samiei F
J Gastrointest Cancer; 2019 Dec; 50(4):907-912. PubMed ID: 30402826
[TBL] [Abstract][Full Text] [Related]
34. Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment.
DeMeester SR
Ann Surg Oncol; 2006 Jan; 13(1):12-30. PubMed ID: 16378161
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy for Esophageal Adenocarcinoma.
Lam KO; Kwong DLW
Methods Mol Biol; 2018; 1756():19-34. PubMed ID: 29600357
[TBL] [Abstract][Full Text] [Related]
36. [Modern diagnostics and stage-oriented surgery: therapy of adenocarcinoma of the esophagogastric junction].
Hölscher AH; Fetzner UK
Chirurg; 2012 Aug; 83(8):702-8, 710-1. PubMed ID: 22878576
[TBL] [Abstract][Full Text] [Related]
37. [Survival comparison of Siewert II adenocarcinoma of esophagogastric junction between transthoracic and transabdominal approaches:a joint data analysis of thoracic and gastrointestinal surgery].
Yang S; Yuan Y; Hu H; Li R; Liu K; Zhang W; Yang K; Yang Y; Bai D; Chen X; Zhou Z; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):132-142. PubMed ID: 30799535
[TBL] [Abstract][Full Text] [Related]
38. Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ?
Kneuertz PJ; Hofstetter WL; Chiang YJ; Das P; Blum M; Elimova E; Mansfield P; Ajani J; Badgwell B
Ann Surg Oncol; 2016 Feb; 23(2):626-32. PubMed ID: 26564243
[TBL] [Abstract][Full Text] [Related]
39. [Understanding and controversy of the gastroesophageal junction adenocarcinoma].
Zhang XH; Wang QZ
Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):947-9. PubMed ID: 19174001
[No Abstract] [Full Text] [Related]
40. Treatment of esophagogastric junction carcinoma: an unsolved debate.
Orditura M; Galizia G; Lieto E; De Vita F; Ciardiello F
World J Gastroenterol; 2015 Apr; 21(15):4427-31. PubMed ID: 25914451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
